Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "PARP Inhibitor Biomarkers Market by Product, Service, Application, End User, and Region" report has been added to ResearchAndMarkets.com's offering. This ...

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a phase I clinical trial—causes DNA damage in cancer cells which is ...

The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo ...

Thanks to the work of Fred Hutch/University of Washington clinical researchers, a big discovery may soon make a “big, big ...

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...

Five branded products, four tumor types, and a regulatory arc that walked back late-line ovarian approvals even as AKEEGA just reached hormone-sensitive prostate cancer.